Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice - PubMed (original) (raw)

Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice

P N Gilles et al. J Virol. 1992 Jun.

Abstract

It is well known that several inflammatory cytokines can modulate hepatocellular gene expression in a complex physiological process known as the hepatic acute-phase response. Since hepatitis B virus (HBV) characteristically induces a vigorous lymphomononuclear inflammatory response in the liver during acute and chronic hepatitis, it is possible that hepatocellular HBV gene expression may also be modulated by one or more of the cytokines produced by these cells. Using bacterial lipopolysaccharide (LPS) as a surrogate inducer of inflammatory cytokines in vivo, we have tested this hypothesis in a transgenic mouse model system. In experiments with two independent transgenic mouse lineages that express the HBV envelope region under the control of either HBV or cellular promoters, we observed a 50 to 80% reduction in the hepatic steady-state content of a 2.1-kb HBV mRNA following administration of a single intraperitoneal dose of LPS. The regulatory influence of several inflammatory cytokines known to be induced by LPS was also examined in this system. The negative regulatory effect of LPS was consistently reproduced by the administration of a single nontoxic dose of tumor necrosis factor alpha, and it was occasionally observed following the administration of high doses of alpha interferon and interleukin-6, while no effect was detectable in response to high-dose interleukin-1 alpha or to gamma interferon. These observations suggest that tumor necrosis factor alpha and perhaps other cytokines may activate a heretofore unsuspected intracellular pathway that negatively regulates HBV gene expression. The intracellular mechanism(s) responsible for this effect and its pathophysiologic relevance remain to be elucidated.

PubMed Disclaimer

Cited by

Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.
Jacquard AC, Nassal M, Pichoud C, Ren S, Schultz U, Guerret S, Chevallier M, Werle B, Peyrol S, Jamard C, Rimsky LT, Trepo C, Zoulim F. Jacquard AC, et al. Antimicrob Agents Chemother. 2004 Jul;48(7):2683-92. doi: 10.1128/AAC.48.7.2683-2692.2004. Antimicrob Agents Chemother. 2004. PMID: 15215126 Free PMC article.
Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte.
Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, Mason WS. Kajino K, et al. J Virol. 1994 Sep;68(9):5792-803. doi: 10.1128/JVI.68.9.5792-5803.1994. J Virol. 1994. PMID: 7914548 Free PMC article.
Hepatitis B virus immunopathology.
Chisari FV, Ferrari C. Chisari FV, et al. Springer Semin Immunopathol. 1995;17(2-3):261-81. doi: 10.1007/BF00196169. Springer Semin Immunopathol. 1995. PMID: 8571172 Review.
La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA.
Heise T, Guidotti LG, Chisari FV. Heise T, et al. J Virol. 1999 Jul;73(7):5767-76. doi: 10.1128/JVI.73.7.5767-5776.1999. J Virol. 1999. PMID: 10364328 Free PMC article.
Hepatitis B virus persistence after recovery from acute viral hepatitis.
Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Michalak TI, et al. J Clin Invest. 1994 Jan;93(1):230-9. doi: 10.1172/JCI116950. J Clin Invest. 1994. PMID: 8282792 Free PMC article.

References

1. Anal Biochem. 1987 Apr;162(1):156-9 - PubMed
1. Proc Natl Acad Sci U S A. 1979 May;76(5):2222-6 - PubMed
1. J Clin Invest. 1986 Nov;78(5):1349-54 - PubMed
1. J Immunol. 1988 Jan 1;140(1):108-11 - PubMed
1. Biochem Pharmacol. 1988 Jul 1;37(13):2569-73 - PubMed

Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice - PubMed (original) (raw)